When brand-name drug companies go to court, it’s usually to fight with a generic competitor. But that’s changing. More than ever before, brand-name drug companies are bringing patent cases against each other. Patent litigators say the “brand vs. brand” trend is here to stay, so legal departments may need to rethink some strategies.
The most recent court fight between brand-name drug companies kicked off on Dec. 5 when Bayer sued Baxalta Inc., alleging that Baxalta’s blood clotting treatment Adynovate infringes one of its patents. According to Bayer’s complaint, Baxalta improperly used technology developed by a former Bayer collaborator, Nektar Therapeutics, which is also a named defendant.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
